表紙
年間契約型資訊服務

Epiomic(TM)疾病·治療類別患者人口資料庫

Epiomic Patient Segmentation Database

出版商 Black Swan Analysis 商品編碼 345452
出版日期 年間契約型資訊服務 內容資訊 英文
價格
如有價格方面的疑問請按下「詢問」鍵來信查詢
Epiomic(TM)疾病·治療類別患者人口資料庫 Epiomic Patient Segmentation Database
出版日期: 年間契約型資訊服務內容資訊: 英文
簡介

何謂Epiomic

Epiomic患者市場區隔資料庫是有助於醫療及醫藥品業界為求更高水準之流行病學分析所用。患者的生命徵象和病理學、共生病症等基本發病資料或患病資料互相疊合比較,可得出更正確的患者市場區隔。藉此便能更精準踏實地評估及預測產品。

商業性及策略性投資計劃

Epiomic患者市場區隔資料庫可提供您一個支援可靠評估、產品預測或鎖定具有高度可能性之市場區隔之強力基礎。藉由活用更具體之患者人口,便可控制偏差,降低在準備所需產品標示時的風險。醫療經濟學,結果研究及打入市場

預算影響分析

Epiomic資料庫由於是以國家為單位,迅速定量評估患者總數,因此關係到產品標示。雖然迄今要決定合規之患者總數是個相當困難的作業,但藉由這個資料庫,便可讓您簡潔、迅速且直接影響預算評估。

臨床實驗開發

使用Epiomic資料庫,您可基於特定疾病方面之重要屬性、年齡、性別…或是治療方面之併發症迅速決定患者市場區隔。

25年預測您可鎖定這段期間上特定疾病總患者數。使用同樣的簡介側寫,可驗証6大市場,了解所有國家中患者數最多之國家,並可鎖定其地位及必要的臨床sites數。

網羅的地區

這個資料庫第一先網羅了大部分疾病之全球8大醫藥品市場,部分疾病甚至可擴大到17個市場。

何謂這個資料庫的獨家性

  • 品質 - 活用來自登記患者、臨床實驗、流行病學研究得來的最新可利用資料,可預測正確的患者人口。
  • 廣度與深度 - 網羅145種疾病。這裡包含了超過11,500的亞總體,標示出從那些患者可見的臨床性重要特性和許多共生病症。
  • 通融性 - 用戶可選定疾病資料、性別、以5歲為單位的年齡群別,以及指定用戶之生物矩陣分佈(案例:BMI、腎功能、血壓)的10年預測。
  • 人性化 - 直覺的客戶介面,如同網站內導航,您可輕易找到各種疾病及子集團中的導航。
  • 容易使用 - 您可用貴社固有的格式導入該資料。也可導入為醫藥品產業一般使用的表(圖表)模板。
  • 特別訂製 - 並非定期購買而僅隊一次,您有機會取得特定疾病相關的指定資料。

調查對象疾病範例

  • 肺·呼吸系統疾病
    • 囊狀纖維化症
    • 特發性肺纖維化
  • 缺乏性障礙
    • 腦及肌腱黃瘤病
    • 生長激素缺乏症
    • 原發性肉鹼缺乏症
  • 心臟血管系統疾病
    • 原發性血小板增多症
    • 真性多血症
    • 慢性血栓栓塞性肺高血壓
    • 肺動脈高血壓
    • 鐮狀細胞貧血
  • 腦神經系疾病
    • 血管性癡呆症
    • 亨丁頓舞蹈症
    • 腦性麻痺
    • 高雪氏症
    • 法布瑞氏症
  • 自體免疫疾病
    • 肌肉萎縮性側索硬化症(俗稱漸凍人)
    • 全身性紅斑性狼瘡
    • 韋格納肉芽腫
    • 愛迪生氏症
    • 白塞氏病
  • 腸胃疾病
    • 克隆氏症
    • 乳糜瀉
  • 癌症
    • 膀胱癌
    • 腦瘤
    • 子宮頸癌
    • 白血病 (全部的類型)
    • 大腸癌
    • 膽囊癌
    • 何杰金氏淋巴瘤
    • 多發性骨髓瘤
    • 一次性骨髓纖維化
    • 胰臟癌
    • 胃癌
    • 睪丸癌

調查對象國家

  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 巴西

調查對象國家 (部分疾病)

  • 印度
  • 中國
  • 俄羅斯
  • 澳洲
  • 加拿大
  • 阿根廷
  • 墨西哥
  • 荷蘭
  • 韓國
  • 土耳其
  • 希臘
  • 捷克
  • 波蘭
目錄

A Systematic Methodology

Finding and properly assessing strong sources of epidemiological data is more important than ever before in the age of evidence-based medicine. At Black Swan Analysis, we ensure that each disease area utilises a multitude of relevant and high-quality sources that are validated using internal and external sources to build an extensive, accurate online database.

  •  
  • Using rigorous search algorithms, we extract the latest data and research. Stringent review criteria are employed to scrutinize data relevance.
  •  
  • Data is analysed using tools and methods including meta-analyses, logistic regression and patient models to interrogate data.
  •  
  •  
  • Datasets are peer-reviewed by our team of experts to ensure that they are comprehensive and relevant.
  •  
  •  
  •  
  • ease areas are published online to the EpiomicTM Database for timely access.
  •  


The Epiomic™ Database

liable data source to better understand your patient population

The Epiomic™ Database is an evidence-based source for patient populations . Going beyond basic prevalence or incidence, patient populations are segmented according to biomarkers, clinical parameters and/or co-morbid conditions.

By providing more detailed segmentation, these refined populations provide the fundamental building blocks for more accurate and robust asset valuations and forecasts .

Utilising the latest research, datasets are constructed using a wide variety of sources and reliable tools and techniques, resulting in a strong and defendable analysis of the epidemiology.

Disease Coverage

The Epiomic™ Database covers a comprehensive range of over 200 prominent and rare diseases, including over 9,500 sub-populations, organised into 15 therapeutic categories. Each category includes all relevant diseases for the therapy area with easy navigation between diseases. The data shows a 10-year adjustable forecast (up to 2100) split by gender and 5-year age cohorts giving a very detailed perspective of each condition's population.

  • 15 Therapeutic categories
  • 200+ Diseases
  • 9,500+ Sub-populations


Robust and Reliable

  • The Epiomic™ Database is rigorous enough to stand up to scrutiny from regulatory bodies.

Rare Disease Coverage

  • Applying proprietary incidence disease modelling techniques which incorporate the often-limited patient data available for rare diseases, we have generated estimated numbers of patients for 35+ rare diseases.

Quality

  • Utilising the most up-to-date information from patient registries, clinical trials and epidemiology studies we have generated accurate patient population estimates. All diseases are routinely updated every 12 months, with more frequent updates to diseases of greater interest and focus on publications.

Breadth and Depth

  • Covering 200+ diseases and data for over 27 countries and continuously growing
  • Including 9,500+ unique sub-populations
  • Extensive in-patient data: hospital admissions and procedures data is available by ICD-9 and ICD-10 codes

Flexibility

  • Subscribers can select data for a 10-year (adjustable) forecast period split by gender and 5-year age cohort
  • Biometric distributions: specify cut-points for population distributions, such as blood pressure, lipid profile, lung function, BMI, kidney function etc, to generate unique patient segments within the overall disease

Ease

  • An intuitive online interface makes it simple to navigate through the site and filtering different diseases and sub-populations. With rapid access to data, easy extraction and quick Excel downloads

Targeted Solutions to Match Your Business Needs

Choose from options such as annual online database subscription, ready-to-use disease reports or completely customised analysis with extensive analyst support.

*Online subscribers have instant access to live data updates. Data reports can be customised and delivered within 24 hours of request depending on the level of customisation requested. Delivery of fully custom analysis depends on scope but tends to be within 3-4 weeks.

Geographic Coverage

The EpiomicTM Database provides global coverage to make business decisions clear .

A minimum of 85% of indications are covered for 27 major global markets

This is a live database and is updated regularly.

We can help with;

  • Independent review and analysis of your current data
  • Quantifying eligible populations for unique asset indication labels
  • Providing customised data that is easy to use
  • Supporting documentation and detailed explanations for regulatory submissions and due diligence